Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Abstract Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated. Here we report results from a comparative clinical study that evaluated the efficacy and safet...

Full description

Bibliographic Details
Main Authors: Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Arthritis Research & Therapy
Subjects:
ABP 710
Infliximab
Biosimilar
Rheumatoid arthritis
Online Access:http://link.springer.com/article/10.1186/s13075-020-2142-1

Internet

http://link.springer.com/article/10.1186/s13075-020-2142-1

Similar Items